Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Altamira Therapeutics Ltd (CYTO)

Altamira Therapeutics Ltd (CYTO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to $7.4 Billion By 2032 FinancialNewsMedia - Fri May 24, 7:45AM CDT

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:RENB),(NASDAQ:CYTO),(NYSE:PFE),(NYSE:ABBV) EQNX::TICKER_END

ONCY : 1.0300 (unch)
ONC.TO : 1.41 (+0.71%)
RENB : 1.5400 (-3.75%)
CYTO : 1.2200 (-4.69%)
PFE : 27.93 (-0.43%)
ABBV : 166.52 (-0.44%)
Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to $7.4 Billion By 2032 GlobeNewswire - Fri May 24, 7:45AM CDT

ONCY : 1.0300 (unch)
ONC.TO : 1.41 (+0.71%)
RENB : 1.5400 (-3.75%)
CYTO : 1.2200 (-4.69%)
PFE : 27.93 (-0.43%)
ABBV : 166.52 (-0.44%)
Altamira Therapeutics’ (NASDAQ: CYTO) Clinical Data on Bentrio Showing Strong Nasal Residence and Rheological Properties Spotlight Growth - Fri Mar 3, 2023

Altamira Therapeutics, Ltd. (NASDAQ: CYTO) is engaged within the research and development of RNA-based therapies for extrahepatic targets and unmet

CYTO : 1.2200 (-4.69%)
Altamira Therapeutics’ CEO Interviewed by Proactive Investors to Discuss its Pipeline of RNA Therapeutics and Ongoing Strategic Transformation Globe Newswire - Wed Aug 3, 2022

HAMILTON, BERMUDA , Aug. 03, 2022 (GLOBE NEWSWIRE) -- Altamira’s patented RNA delivery technology platform is addressing strong need for reaching target...

CYTO : 1.2200 (-4.69%)
Altamira Therapeutics Completes Interim Sample Size Analysis of COVAMID Trial with Bentrio in Acute COVID-19 Globe Newswire - Mon Aug 1, 2022

HAMILTON, BERMUDA , Aug. 01, 2022 (GLOBE NEWSWIRE) -- Enrollment to be continued to 160 subjects, adding 24 to ensure adequate statistical powerTop-line...

CYTO : 1.2200 (-4.69%)
Altamira Therapeutics’ Delivery Platform with siRNA Shown to be Effective Treatment for Osteoarthritis as Published in Peer-Reviewed Journal Globe Newswire - Thu Jul 28, 2022

•Independent peer-reviewed study confirms high potential for OligoPhoreTM delivery platform in RNA-based treatments for osteoarthritis •Knock down of...

CYTO : 1.2200 (-4.69%)
Altamira Therapeutics to Develop Novel Generation of Rheumatoid Arthritis Therapeutics Based on its Proprietary OligoPhore Delivery Platform and siRNA Targeting Key Inflammation Checkpoint Globe Newswire - Mon Jul 25, 2022

•Company’s novel drug development program AM-411 builds on positive animal data •Treatments for rheumatoid arthritis represent the second largest...

CYTO : 1.2200 (-4.69%)
Altamira Therapeutic's SemaPhore Platform Shown Particularly Effective in Intracellular mRNA Delivery for Cancer Therapy Globe Newswire - Tue Jul 19, 2022

Peer-reviewed study highlights high potential for cell-penetrating peptides in mRNA-based cancer treatmentsDemonstrates effective uptake and...

CYTO : 1.2200 (-4.69%)
Altamira Therapeutic’s RNA Delivery Platform Shown to be an Effective Treatment for Abdominal Aortic Aneurysm as Published in Peer-Reviewed Journal AccessWire - Tue Jul 12, 2022

HAMILTON, BERMUDA / ACCESSWIRE / July 12, 2022 / Altamira Therapeutics ("Altamira" or the "Company") (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs,...

CYTO : 1.2200 (-4.69%)
Altamira Therapeutics Secures Marketing & Distribution Agreements To Expand Sales Channels of Bentrio into Egypt and Pakistan AccessWire - Wed Jun 29, 2022

Two Additional Distributors Further Expand Company's Growing Global Footprint To Offer Its Bentrio Nasal Spray for Protection Against Airborne Allergens and Viruses

CYTO : 1.2200 (-4.69%)

Barchart Exclusives

Should You Follow Insider Buying In This Large-Cap Semiconductor Stock? Barchart - Mon Jul 8, 10:17AM CDT
Marvell Technology is an AI-based chip maker that should outpace broader market returns in 2024. Let's see why. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot